2011 First Half Net Sales
Sustained rebound in sales.
The Group rebounded strongly from the end of 2010 on renewed growth momentum in first half of this year. Sales were up 3% in Europe and 23% in other regions compared to last year, with significant sales growth for Lipiodol in the USA. Sales outside Europe accounted for 75% of the Group's growth.